TiGenix , the European leader in cell therapy, today announced positive 6-month safety data of its Phase IIa study of Cx611 in rheumatoid arthritis , as well as a first indication of therapeutic activity on standard outcome measures and biologic markers of inflammation for at least three months after dosing.
http://www.biospace.com/news_story.aspx?StoryID=293985&full=1
http://www.biospace.com/news_story.aspx?StoryID=293985&full=1
No comments:
Post a Comment